NAPWA

Generic name:	efavirenz + emtricitabine + tenofovir
Pronunciation:	Ah-TRIP-la
Brand name:	Atripla
Drug class:	multi-class formulation
Pregnancy safe?	Not suitable for use in pregnancy. If you are pregnant or may become pregnant, you should not take this treatment.
Availability in Australia:	Available on the Pharmaceutical Benefits Scheme (PBS) through S100 prescribers since 2010. You may be able to import this drug from overseas for your personal use. Atripla has been available on PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. from 1 January 2010.
Presentation:	600 mg efavirenz; 200 mg emtricitabine; 300 mg tenofovir disoproxil fumarate

This product contains multiple medicines which comprise a complete antiretroviral regimen for most people. However your doctor may prescribe other antiretrovirals to be taken in combination with efavirenz + emtricitabine + tenofovir if needed. Your doctor will advise you on the right combination of drugs to suit your circumstances.

Dosage

The normal adult dose is one tablet once a day preferably at bedtime.

Regardless of what you read on this website or elsewhere, you should always take your medications according to your doctor's instructions. If you're unsure, speak to your doctor or pharmacist.

With or without food?

Efavirenz + emtricitabine + tenofovir must be taken on an empty stomach.

Side effects

All drugs can produce side effects in some people. These may be mild, moderate or severe, so you should be aware of potential side effects before starting any drug, and speak to your doctor if you experience side effects that concern you.

• Common side effects may include nausea (upset stomach, feeling sick to the stomach), diarrhoea, headache, fatigue, vivid dreams, dizzyness.
• Less common side effects may include nervous system symptoms, psychiatric symptoms, rash..

It's unlikely you will experience all of these side effects, and you may not experience any side effects at all. Before starting any new drug, ask your doctor about side effects you might experience and discuss strategies for dealing with side effects if they do occur. If you experience any significant side effect you should continue taking your medicine and see your doctor as soon as possible.

Interactions with other drugs

Atripla should not be taken with midazolam, triazolam, or ergot derivatives because competition for CYP3A4 liver enzymes by efavirenz could result in the inhibition of metabolism of these drugs and could create the potential for serious adverse events, including cardiac arrhythmias, prolonged or increased sedation and respiratory depression. Atripla should not be co-administered with voriconazole, because efavirenz significantly decreases voriconazole plasma concentrations. Atripla use is contraindicated with pimozide and St. John's wort. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. The safety of Atripla has not been established in patients coinfected with HIV and hepatitis B virus (HBV). Severe acute exacerbations of HBV have been reported in patients who have discontinued emtricitabine or tenofovir DF. Hepatic function should be monitored closely for at least several months in patients who discontinue Atripla and are coinfected with HIV and HBV. If appropriate, initiation of HBV therapy may be warranted. Atripla is not indicated for use in patients coinfected with HIV and chronic HBV. Because of the nature of the fixed-dose combination tablet, Atripla should not be used in combination with the individual component medications efavirenz, emtricitabine, and tenofovir DF. In addition, because of similarities between emtricitabine and lamivudine, Atripla should not be co-administered with drugs containing lamivudine, including the brand medications Combivir, Epivir, Epzicom, or Trizivir.

Attachment	Size	Type
Atripla consumer release _FINAL_embargo 091217 (2).pdf	110.88 KB	PDF
Fact Sheet_ATRIPLA_Final _Dec 09.pdf	108.24 KB	PDF
DeJesus_073_JAIDS_ePub.pdf	227.66 KB	PDF
DeJesus_934E ICAAC 2008.pdf	92.45 KB	PDF
Stone_J Acquir Immune Defic Syndr_2004.pdf	42.76 KB	PDF

The table below shows all the clinical trials in the database with the keyword Atripla.